FIELD: biotechnology.
SUBSTANCE: invention relates to a fused protein containing in the direction from the N-terminus to the C-terminus a DNA methyltransferase domain, an enzyme nuclease-deficient RNA-directed DNA endonuclease and a domain associated with Krüppel box or Krüppel box related domain, the enzyme nuclease-deficient RNA-directed DNA endonuclease and the domain of DNA methyltransferase, as well as the complex containing it. Also a nucleic acid molecule encoding the above fusion protein, as well as a vector and a cell containing it are disclosed.
EFFECT: invention is effective for silencing a target nucleic acid sequence in a cell.
60 cl, 13 dwg, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| COMPOSITION AND USE OF ARGININE-DEPLETING AGENTS IN CANCER, OBESITY, METABOLIC DISORDERS AND RELATED COMPLICATIONS AND COMORBIDITIES | 2019 |
|
RU2826185C2 |
